Skip to main content
Biomedical Reports logoLink to Biomedical Reports
. 2022 Sep 28;17(5):91. doi: 10.3892/br.2022.1574

Role of hyaluronic acid in periodontal therapy (Review)

Ashok Bhati 1,, Hytham Fageeh 1, Wael Ibraheem 1, Hammam Fageeh 1, Harneet Chopra 2, Suman Panda 1
PMCID: PMC9535241  PMID: 36278244

Abstract

Hyaluronic acid (HA) is essential for the function of extracellular matrices in both hard and soft periodontal components. HA plays an important role in the mechanisms underlying inflammation and wound healing. HA is located in periodontal tissues in differing amounts, including non-mineralized tissues, such as gingiva and periodontal ligament, and lower levels located in mineralized tissues, such as cementum and alveolar bone. According to preliminary findings, HA exhibits potential in the regulation of periodontal tissue regeneration and in the treatment of periodontal disease. HA promotes symptomatic relief in both marginal gingiva and deeper periodontal tissues. The present review aimed to examine the role of HA in periodontal therapy, and investigate the current literature supporting its use in periodontal regeneration.

Keywords: hyaluronic acid, hyaluronan, periodontal healing, periodontitis, gingivitis, periodontal regeneration

1. Introduction

Hyaluronic acid (HA), also referred to as hyaluronan, is one of the most predominant glycosaminoglycans in the extracellular matrix (1). In 1934, Karl Meyer and John Palmer extracted HA from the vitreous fluid of the eye of a cow (2). ‘HA’, as it originated from hyalos (meaning glass in Greek), possessed two sugar molecules, one of them being uronic acid. Moreover, this linear polysaccharide exhibits numerous repeating disaccharide units (3). Notably, a healthy adult (weight, 70 kg) possesses ~15 g HA in the body (4). The majority of cells in the human body synthesize HA; thus, it may play a role in a variety of key biological processes. This evidence demonstrates the potential of HA as a therapeutic option (5).

At present, HA is used for the treatment of chronic inflammatory diseases. Notably, periodontal disease is an inflammatory disease involving the periodontium. The mineralized periodontal tissues of alveolar bone and cementum contain very little HA; however, it is necessitated by the extracellular matrix of the gingiva and the periodontal ligament (4). Wound healing is accelerated following treatment with HA, due to the subsequent impact on HA receptors, which play a role in cellular migration, angiogenesis and inflammation. HA relieves symptoms, both in the marginal gingiva and deeper periodontal tissues (6). This wound-healing characteristic of HA has also been used in different periodontal treatments, involving non-surgical and surgical therapy, and soft and hard tissue regeneration. Moreover, HA plays a crucial role in cell signaling and hemostasis, and manages the cell-matrix and cell-cell exchanges. HA also plays role in the inflow and outflow of nutrients and waste products (7). Notably, HA may be used in periodontal research due to the extensive scope of applications, which are summarized in the present review. No systemic search strategy was performed for the review. An online search was performed for studies, without a specific time frame, using key words (hyaluronic acid, periodontics, periodontal therapy, periodontal regeneration and wound healing) in combination.

2. Properties of HA

HA plays a variety of roles in the body, leveraging physicochemical and biological properties. These biological functions vary from basic structural roles in the extracellular matrix to developmental regulation via effects on cell behaviour through tissue macro and microenvironment control. These functions of HA also exert direct receptor-mediated effects on gene expression (8,9). HA exhibits hygroscopic and viscoelastic properties. Hydrogen and adjacent carboxyl and N-acetyl group bonding occurs after HA is absorbed by an aqueous solution, allowing HA to maintain conformational rigidity through water retention (10). Through maintaining gaps and preserving surfaces, HA modifies the surrounding cellular and extracellular micro and macro environments. HA exhibits bacteriostatic activity, and this was demonstrated to be the highest when high concentrations of medium and lower molecular weight HA were used (11). HA is biocompatible and non-immunogenic in nature. Esterification and cross-linking are two modifications of HA that provide a gel-like structure and rigidity for cell seeding (12). In addition, HA exhibits anti-inflammatory properties. It performs scavenging actions, through the clearing of prostaglandins, metalloproteinases and other bioactive molecules (12). HA also exhibits antioedematous properties associated with osmotic action (13), and antioxidant properties. HA scavenges reactive oxygen species; thus, stabilizing the granulation tissue matrix (14).

3. Synthesis of HA

HA is a negatively charged glycosaminoglycan that differs from other glycosaminoglycans. HA synthesis occurs in the cellular plasma membrane in mammals, whereas glycosaminoglycan synthesis often occurs in the Golgi apparatus. Moreover, HA synthesis occurs via three hyaluronan synthase isoenzymes (HAS1, 2 and 3) (7). HA exhibits a high molecular weight of 103-104 kDa, a length of 2-25 µm, and it does not contain any sulphate groups (8). The synovial fluid, epidermis, umbilical cord and other tissues exhibit the highest concentrations of HA, while the blood serum exhibits the lowest concentration (15). A membrane-bound protein present in plasma membranes produces HA through the transportation of activated monosaccharides to glycosaminoglycan chains, and the release of uridine diphosphate, secreted directly into the extracellular space. Lymphatic drainage into the circulatory system or local metabolism causes HA turnover in tissues. Depending on its removal, HA exhibits a tissue half-life ranging from 12 h to 2-3 days (16).

4. Role of HA in wound healing

HA plays a role in numerous physiological and biological processes, serving as a structural component of cartilage and other tissues. To produce proteoglycans, HA interacts with proteins rich in numerous forms of glycosaminoglycans. It increases inflammatory cell and extracellular matrix infiltration, assisting inflammation. Thus, HA exhibits the potential to impact cellular behaviour via influencing the environment surrounding cells (16). HA is engaged in numerous cell functions which increase tissue healing, such as cell proliferation, locomotion and recognition. This makes HA increasingly susceptible to colonization by tissue repair cells (17). In its highly purified form, HA has been used in medicine for a number of years, due to its physiochemical characteristics and non-immunogenicity. As HA retains water in large amounts, it affects and improves tissue regeneration; thus, preventing the production of scabs and scars (18,19). It has been proposed that HA stimulates angiogenesis, leading to increased levels of wound healing in the bone matrix. At a low molecular weight, HA is angiogenic, whereas at a high molecular weight, HA is anti-angiogenic (20). High molecular weight HA enhances osteo-induction or bone production during wound healing (21). Results of previous studies demonstrated that exogenous HA exerted satisfying wound healing benefits (22-24). In cosmetic dermatology, HA is also used as a dermal filler (25). As it forms an integral part of cell migration, organogenesis and development, HA exhibits potential in tissue engineering (26). The esterification and crosslinking of HA are two modifications that provide the gel-like structure and rigidity for cell seeding. These biopolymers are biodegradable which help fibroblasts, chondrocytes and mesenchymal stem cells to proliferate (27). HA has been employed as a chemotherapeutic agent in the treatment of gingivitis. Moreover, osseointegration of dental implants indicates the involvement of HA (28). As HA exhibits bone induction properties, it may exhibit potential as a biomaterial scaffold in guided bone regeneration and tissue engineering (29). In 2022, Ibraheem et al (30) demonstrated improved wound healing in extraction socket wounds following treatment with HA. Moreover, HA exhibited dose-dependent bacteriostatic effects on a range of microorganisms in the planktonic phase (31).

Hylauronan generates cell responses via interaction with cell receptors. Notably, there are numerous different cell receptors involved in HA signaling. The most common receptor involved in HA signaling is CD44(32). CD44 signaling plays a crucial role in wound healing, as CD44 in fibroblasts is required for emigration into the affected region (33). Notably, receptor for hyaluronan-mediated motility (RHAMM), also known as CD168, plays a key role in signaling. RHAMM-hyaluronan interactions are vital for tissue repair and inflammation (34). In addition, hyaluronan receptor for endocystosis is involved in hyaluronan endocysotsis, and lymphatic vessel endothelial hyaluronan receptor 1 plays a role in the regulation of tissue hydration and other biochemical properties, via the absorption of HA in the lymphatic system (35,36).

Toll-like receptors are involved in innate immune response, tissue metabolism and tissue haemostasis (37). Toll-like receptors prompt the synthesis of defesins, which possess antibacterial properties and employ regenerative stimuli for cells (38). The molecular weight of HA is an important aspect in HA signaling. Notably, HA induces different signaling pathways at different molecular weights (39).

5. Role of HA and overview of studies in periodontal therapy

HA is located in the periodontium in differing amounts. There are higher levels in the gingiva and periodontal ligament, compared with the cementum and alveolar bone. Moreover, high amounts of HA in the circulatory blood serum represent a serum overload factor of gingival crevicular fluid (40).

Scaling and root planing (SRP) exerts a positive effect on periodontal parameters, as it decreases the pathogens present in the periodontal pocket and alters the microflora to be less pathogenic (41). Results of previous studies investigating SRP combined with non-mechanical therapy demonstrated that the use of local or systemic antibacterial medicines further improved clinical parameters (42,43). However, systemic antibiotics should not be utilized to treat all types of periodontitis. Limiting the use of systemic antibiotics is vital as the development of resistance and unwarranted drug interactions may occur. In patients with gingivitis and chronic periodontitis, HA is utilized as an adjuvant therapy following SRP. Treatment with HA results in a reduction in prostaglandins, metalloproteinases and bioactive materials. This results in the impediment of tissue destruction; thus, promoting healing (44).

Notably, Sahayata et al (45) used 0.2% HA gel (Gengigel®) topically in patients with gingivitis. Results of this previous study demonstrated that HA treatment led to decreased gingival bleeding, reduced gingival fluid flow and improved gingival health (43,44). Moreover, Pilloni et al (46) investigated the effects of HA on periodontal parameters in patients with periodontitis. Results of this previous study demonstrated improved outcomes in the HA group compared with the non-HA group, indicated by significant improvements in bleeding on probing (46). In addition, Pistorius et al (47) also demonstrated improvements in bleeding following treatment with HA. Eick et al (48) evaluated the effects of HA with SRP and SRP alone in patients with chronic periodontitis. Results of this previous study demonstrated a significantly higher reduction in probing pocket depth (PPD) in the SRP + HA group, compared with the use of SRP alone (48).

Improvements have been observed in healing, periodontal indices and clinical attachment level (CAL) following treatment with HA. In a split-mouth study, Al-Shammari et al (49) evaluated the effects of SRP + HA and SRP alone in patients with chronic periodontitis. Improvements in gingival indices, CAL and PPD were observed following 6 and 12 weeks in the test group (49). In addition, Madkour et al (50) assessed the effects of HA in patients with chronic periodontitis under medication. Comparable with the results obtained by Al-Shammari et al (49), the levels of gingival indices, PPD and CAL were improved in both groups, but these levels were most improved in the SRP + HA group (50). Eliezer et al (51) also conducted a systematic review, which demonstrated that HA offers beneficial effects in pocket depth reduction, CAL gain and reduction in bleeding on probing during both surgical and non-surgical periodontal therapy.

HA improved CAL and boosted keratinization. Treatment with injectable HA gel of various doses led to improvements in papillary regeneration, as HA promotes neovascularization (52). Çankaya and Tamam compared the interdental papillary fill after HA was injected into the maxillary and mandibular jaws. The injection was delivered until the color of the gingiva changed to white. After 3, 12 and 24 months, the interdental area demonstrated 54.21, 73.22 and 79.35% coverage remaining in the maxilla, and 57.24, 71.40 and 78.71% coverage remaining in the mandible, respectively (52). Hyaluronan promotes fibroblast attachment to the cementum, while also acting as an antibacterial agent. Moreover, sodium hyaluronate enhances chemical signaling between cells. As a result, sodium hyaluronate is often used in the guided tissue regeneration membrane (GTR) (53). Notably, Vanden Bogaerde (54) examined the clinical effectiveness of esterified HA fibers in the treatment of 18 periodontal defects. The mean PPD was decreased by 5.8 mm after a follow-up of 12 months, and the CAL increase was 2.8 mm (54). In a histological examination in experimental animals, novel alveolar bone growth was observed in bone lesions (55). In 2022, a systemic review by Rodríguez-Aranda et al (56) also demonstrated favourable results with HA in periodontal regeneration. This systemic review revealed improvements in terms of CAL, PPD, BOP, and radiographic parameters, when HA was used alone or in combination with bone graft or other biomaterials (56).

Collectively, the results of previous studies have demonstrated the effective use of HA in periodontal therapy. An overview of studies using HA as a periodontal therapeutic intervention with different sample sizes and HA forms are presented in Table I (49,57-69).

Table I.

Overview of studies using HA in periodontal therapy.

Study Sample size HA Form Intervention Inference Periodontal Therapy
Nguyen et al, 2021(57) 28 chronic periodontitis patients 0.2% HA gel HA + SRP vs. SRP HA showed a greater reduction in BOP and PPD Non-surgical periodontal therapy
Al-Shammari et al, 2018(49) 24 chronic periodontitis patients 0.8% HA gel HA + SRP vs. SRP HA showed a greater reduction in BOP and PPD Non-surgical periodontal therapy
Rajan et al, 2014(58) 33 chronic periodontitis patients HA gel HA + SRP vs. SRP HA showed a greater reduction in BOP and PPD Non-surgical periodontal therapy
Pilloni et al, 2019(59) 30 patients single Miller's Class I recession HA gel HA + CAF vs. CAF 80% complete root coverage for HA and 33.3% complete root coverage for control sites Recession coverage
Kumar et al, 2014(60) 10 patients with Miller's Class I recession HA gel HA + CAF vs. CAF HA group clinically more stable Recession coverage
Pitale et al, 2021(61) 25 patients with Class I and II papillary recession Injection HA gel - Significant difference in black triangle height and width Papilla regeneration
Mansouri et al, 2013(62) 21 interdental papilla deficiencies HA gel - 43% of samples showed 50% or higher improvement Papilla regeneration
Babgi et al, 2020(63) 15 single-rooted teeth HA gel SRP or EDTA or CHX gel SRP highest improvement followed by the HA and CHX groups Root conditioning
Mamajiwala et al, 2021(64) 20 chronic periodontitis patients with 40 infrabony defects HA gel HA gel + OFD vs. OFD + Placebo HA showed significantly greater CAL gain and bone defect fill Regenerative therapy
Bhowmik and Rao, 2021(65) 32 graftable defects HA gel HA + NHA bone graft (H-NHA) vs. NHA alone H-NHA group showed a greater reduction in PPD and defect depth Regenerative therapy
Briguglio et al, 2013(66) 40 subjects with a two-wall infrabony defect HA gel HA + OFD vs. OFD Test group showed significantly greater CAL gain and PPD Regenerative therapy
Sehdev et al, 2016(67) 24 infrabony defects Esterified HA in the form of fibers HA + bioresorbable membrane vs. bioresorbable membrane alone HA showed significantly higher CAL of 2.20 mm Regenerative therapy
Sánchez-Fernández et al, 2021(68) 100 dental implants HA gel HA vs. excipient-based gel vs. no gel PPD was significantly lower in the HA group Therapy for peri-implantitis cases
Dogan et al, 2017(69) 13 systemically healthy patients requiring bilateral two-stage maxillary sinus augmentation (residual crest height ≤4 mm) HA matrix Hyaluronic matrix and collagenated heterologous bone graft vs. collagenated heterologous bone graft Higher percentage of new bone formed in the HA group after 4 months Sinus lift augmentation

HA, hyaluronic acid; SRP, scaling and root planing; BOP, bleeding on probing; PPD, probing pocket depth; CAF, coronally advanced flap; EDTA, ethylenediaminetetraacetic acid; CHX, chlorhexidine; OFD, open flap debridement; NHA, nanohydroxyapatite; CAL, clinical attachment level.

6. Conclusion

HA is a vital biomaterial used in periodontal therapy. Treatment with HA leads to clinical improvement in patients with gingivitis, periodontitis, implants and periodontal defects. Treatment with HA accelerates wound healing, resulting in improved postoperative results and high levels of patient comfort. However, further research into the therapeutic effects of HA in periodontal disease is required. This will further determine the specific uses, the optimal administration of HA for the postoperative treatment of periodontal conditions and the potential for complete periodontal tissue regeneration.

Acknowledgements

Not applicable.

Funding Statement

Funding: No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

AB, HyF, HaF and WI conceived the review. AB performed the literature search. AB, HyF, HaF and WI wrote the manuscript. HC, SP and AB reviewed and edited the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Amorim S, Reis CA, Reis RL, Pires RA. Extracellular matrix mimics using hyaluronan-based biomaterials. Trends Biotechnol. 2021;39:90–104. doi: 10.1016/j.tibtech.2020.06.003. [DOI] [PubMed] [Google Scholar]
  • 2.Meyer K, Palmer JW. The polysaccharide of the vitreous humor. J Biol Chem. 1934;107:629–634. [Google Scholar]
  • 3.Bansal J, kedige SD, Anand S. Hyaluronic acid: A promising mediator for periodontal regeneration. Indian J Dent Res. 2010;21:575–578. doi: 10.4103/0970-9290.74232. [DOI] [PubMed] [Google Scholar]
  • 4.Aydinyurt HS, Akbal D, Altindal D, Bozoglan A, Ertugrul AS, Demir H. Evaluation of biochemical and clinical effects of hyaluronic acid on non-surgical periodontal treatment: A randomized controlled trial. Ir J Med Sci. 2020;189:1485–1494. doi: 10.1007/s11845-020-02230-6. [DOI] [PubMed] [Google Scholar]
  • 5.Abatangelo G, Vindigni V, Avruscio G, Pandis L, Brun P. Hyaluronic acid: Redefining its role. Cells. 2020;9(1743) doi: 10.3390/cells9071743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Casale M, Moffa A, Vella P, Sabatino L, Capuano F, Salvinelli B, Lopez MA, Carinci F, Salvinelli F. Hyaluronic acid: Perspectives in dentistry. A systematic review Int J Immunopathol Pharmacol. 2016;29:572–582. doi: 10.1177/0394632016652906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Vigetti D, Karousou E, Viola M, Deleonibus S, De Luca G, Passi A. Hyaluronan: Biosynthesis and signaling. Biochim Biophys Acta. 2014;1840:2452–2459. doi: 10.1016/j.bbagen.2014.02.001. [DOI] [PubMed] [Google Scholar]
  • 8.Toole BP. Hyaluronan is not just a goo! J Clin Invest. 2000;106:335–336. doi: 10.1172/JCI10706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: An information rich system. Eur J Cell Biol. 2006;85:699–715. doi: 10.1016/j.ejcb.2006.05.009. [DOI] [PubMed] [Google Scholar]
  • 10.Sutherland IW. Novel and established applications of microbial polysaccharides. Trends Biotechnol. 1998;16:41–46. doi: 10.1016/S0167-7799(97)01139-6. [DOI] [PubMed] [Google Scholar]
  • 11.Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A, Bernard GW. Bacteriostatic effects of hyaluronic acid. J Periodontol. 1999;70:370–374. doi: 10.1902/jop.1999.70.4.370. [DOI] [PubMed] [Google Scholar]
  • 12.Laurent TC, Laurent UB, Fraser JR. Functions of hyaluronan. Ann Rheum Dis. 1995;54:429–432. doi: 10.1136/ard.54.5.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Jentsch H, Pomowski R, Kundt G, Göcke R. Treatment of gingivitis with hyaluronan. J Clin Periodontol. 2003;30:159–164. doi: 10.1034/j.1600-051x.2003.300203.x. [DOI] [PubMed] [Google Scholar]
  • 14.Waddington RJ, Moseley R, Embery G. Reactive oxygen species: A potential role in the pathogenesis of periodontal diseases. Oral Dis. 2000;6:138–151. doi: 10.1111/j.1601-0825.2000.tb00325.x. [DOI] [PubMed] [Google Scholar]
  • 15.Laurent TC, Fraser JRE. The properties and turnover of hyaluronan. Ciba Found Symp. 1986;124:9–29. doi: 10.1002/9780470513385.ch2. [DOI] [PubMed] [Google Scholar]
  • 16.Fraser JR, Laurent TC, Laurent UB. Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med. 1997;242:27–33. doi: 10.1046/j.1365-2796.1997.00170.x. [DOI] [PubMed] [Google Scholar]
  • 17.Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA, Greenley AH. TGF-beta 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J Cell Biol. 1993;123:749–758. doi: 10.1083/jcb.123.3.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nakamura M, Hikida M, Nakano T, Ito S, Hamano T, Kinoshita S. Characterization of water retentive properties of hyaluronan. Cornea. 1993;12:433–436. doi: 10.1097/00003226-199309000-00010. [DOI] [PubMed] [Google Scholar]
  • 19.Adzick NS, Longaker MT. Scarless wound healing in the fetus: The role of extracapsular matrix. Prog Clin Biol Res. 1991;365:177–192. [PubMed] [Google Scholar]
  • 20.West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp. 1989;143:187–207. doi: 10.1002/9780470513774.ch12. [DOI] [PubMed] [Google Scholar]
  • 21.Sakasi T, Watanabe C. Stimulation of osteoinduction in bone wound healing by high-molecular hyaluronic acid. Bone. 1995;16:9–15. doi: 10.1016/s8756-3282(94)00001-8. [DOI] [PubMed] [Google Scholar]
  • 22.Abatangelo G, Martelli M, Vecchia P. Healing of hyaluronic acid-enriched wounds: Histological observations: J Surg. Res. 1983;35:410–416. doi: 10.1016/0022-4804(83)90030-6. [DOI] [PubMed] [Google Scholar]
  • 23.King SR, Hickerson WL, Proctor KG, Newsome AM. Beneficial actions of exogenous hyaluronic acid on wound healing. Surgery. 1991;109:76–84. [PubMed] [Google Scholar]
  • 24.Nakamura M, Hikida M, Nakano T. Concentration and molecular weight dependency of rabbit corneal epithelial wound healing on hyaluronan. Curr Eye Res. 1992;11:981–986. doi: 10.3109/02713689209033496. [DOI] [PubMed] [Google Scholar]
  • 25.Monheit GD, Coleman KM. Hyaluronic acid fillers. Dermatol Ther. 2006;19:141–150. doi: 10.1111/j.1529-8019.2006.00068.x. [DOI] [PubMed] [Google Scholar]
  • 26.Allison DD, Grande-Allen KJ. Hyaluronan: A powerful tissue engineering tool. Tissue Eng. 2006;12:2131–2140. doi: 10.1089/ten.2006.12.2131. [DOI] [PubMed] [Google Scholar]
  • 27.Bartold PM, Xiao Y, Lyngstaadas SP, Paine ML, Snead ML. Principles and applications of cell delivery systems for periodontal regeneration: Periodontol. 2000. 2006;41:123–135. doi: 10.1111/j.1600-0757.2006.00156.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Klinger MM, Rahemtulla F, Prince CW, Lucas LC, Lemonas JE. Proteoglycans at the bone-implant interface: Crit Rev Oral. Med. 1988;9:449–463. doi: 10.1177/10454411980090040401. [DOI] [PubMed] [Google Scholar]
  • 29.Hunt DR, Jovanovic SA, Wikesjö UM, Wozney JM, Bernard GW. Hyaluronan supports recombinant human bone morphogenetic protein-2 induced bone reconstruction of advanced alveolar ridge defects in dogs. A pilot study. J Periodontol. 2001;72:651–658. doi: 10.1902/jop.2001.72.5.651. [DOI] [PubMed] [Google Scholar]
  • 30.Ibraheem W, Jedaiba WH, Alnami AM, Hussain Baiti LA, Ali Manqari SM, Bhati A, Almarghlani A, Assaggaf M. Efficacy of hyaluronic acid gel and spray in healing of extraction wound: A randomized controlled study. Eur Rev Med Pharmacol Sci. 2022;26:3444–3449. doi: 10.26355/eurrev_202205_28838. [DOI] [PubMed] [Google Scholar]
  • 31.Carlson GA, Dragoo JL, Samimi B, Bruckner DA, Bernard GW, Hedrick M, Benhaim P. Bacteriostatic properties of biomatrices against common orthopaedic pathogens. Biochem Biophys Res Commun. 2004;321:472–478. doi: 10.1016/j.bbrc.2004.06.165. [DOI] [PubMed] [Google Scholar]
  • 32.Arfullo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell receptor for hyaluronadate. Cell. 1990;61:1303–1313. doi: 10.1016/0092-8674(90)90694-a. [DOI] [PubMed] [Google Scholar]
  • 33.Clark RA, Lin F, Greiling D, An J, Couchman JR. Fibroblast invasive migration into fibronectin/fibrin gels requires a previously uncharacterized dermatan sulfate-CD44 proteolglycan. J Invest Dermatol. 2004;122:266–277. doi: 10.1046/j.0022-202X.2004.22205.x. [DOI] [PubMed] [Google Scholar]
  • 34.Zaman A, Cui Z, Foley JP, Zhao H, Grimm PC, Delisser HM, Savani RC. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am J Respir Cell Mol Biol. 2005;33:447–454. doi: 10.1165/rcmb.2004-0333OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zhao B, Weigel JA, Saxena A, Weigel PH. Molecular cloning and functional expression of the rat 175-kDa hyaluronan receptor for endocytosis. Mol Biol Cell. 2002;13:2853–2868. doi: 10.1091/mbc.02-03-0048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem. 2001;276:19420–19430. doi: 10.1074/jbc.M011004200. [DOI] [PubMed] [Google Scholar]
  • 37.Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll like receptors is required for intestinal hemostasis. Cell. 2004;118:229–224. doi: 10.1016/j.cell.2004.07.002. [DOI] [PubMed] [Google Scholar]
  • 38.Gariboldi S, Plazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L, Cavacchini S, Balsari A, Rucio C. Low molecular weight hyaluronic acid increases the self defense of skin epithelium by induction of beta defensin 2 via TLR2 and TLR 4. J Immunol. 2008;181:2103–2110. doi: 10.4049/jimmunol.181.3.2103. [DOI] [PubMed] [Google Scholar]
  • 39.Itano N. Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J Biochem. 2008;144:131–137. doi: 10.1093/jb/mvn046. [DOI] [PubMed] [Google Scholar]
  • 40.Embery G, Waddington RJ, Hall RC, Last KS. Connective tissue elements as diagnostic aids in periodontology. Periodontol 2000. 2000;24:193–214. doi: 10.1034/j.1600-0757.2000.2240109.x. [DOI] [PubMed] [Google Scholar]
  • 41.Cugini MA, Haffajee AD, Smith C, Kent RL Jr, Socransky SS. The effect of scaling and root planing on the clinical and microbiological parameter of periodontal diseases: 12-month results. J Clin Periodontol. 2000;27:30–36. doi: 10.1034/j.1600-051x.2000.027001030.x. [DOI] [PubMed] [Google Scholar]
  • 42.Bonito AJ, Lux L, Lohr KN. Impact of local adjuncts to scaling and root planing in periodontal disease therapy: A systematic review. J Periodontol. 2005;76:1227–1236. doi: 10.1902/jop.2005.76.8.1227. [DOI] [PubMed] [Google Scholar]
  • 43.Johannsen A, Tellefsen M, Wikesjo U, Johannsen G. Local delivery of hyaluronan as an adjunct to scaling and root planing in the treatment of chronic periodontitis. J Periodontol. 2009;80:1493–1497. doi: 10.1902/jop.2009.090128. [DOI] [PubMed] [Google Scholar]
  • 44.Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996;74:A1–A7. doi: 10.1038/icb.1996.32. [DOI] [PubMed] [Google Scholar]
  • 45.Sahayata VN, Bhavsar NV, Brahmbhatt NA. An evaluation of 0.2% hyaluronic acid gel (Gengigel ®) in the treatment of gingivitis: A clinical & microbiological study. Oral Health Dent Manag. 2014;13:779–785. [PubMed] [Google Scholar]
  • 46.Pilloni A, Annibali S, Dominici F, Di Paolo C, Papa M, Cassini MA, Polimeni A. Evaluation of the efficacy of an hyaluronic acid-based biogel on periodontal clinical parameters. A randomized-controlled clinical pilot study. Ann Stomatol (Roma) 2011;2:3–9. [PMC free article] [PubMed] [Google Scholar]
  • 47.Pistorius A, Martin M, Willershausen B, Rockmann P. The clinical application of hyaluronic acid in gingivitis therapy. Quintessence Int. 2005;36:531–538. [PubMed] [Google Scholar]
  • 48.Eick S, Renatus A, Heinicke M, Pfister W, Stratul SI, Jentsch H. Hyaluronic Acid as an adjunct after scaling and root planing: A prospective randomized clinical trial. J Periodontol. 2013;84:941–949. doi: 10.1902/jop.2012.120269. [DOI] [PubMed] [Google Scholar]
  • 49.Al-Shammari NM, Shafshak SM, Ali MS. Effect of 0.8% Hyaluronic acid in conventional treatment of moderate to severe chronic periodontitis. J Contemp Dent Pract. 2018;19:527–534. [PubMed] [Google Scholar]
  • 50.Madkour GG, EL Refaie I, Mostafa B. Adjunctive use of hyaluronic acid with scaling and root planing in treatment of chronic periodontitis patients with diabetes mellitus type 2: A randomized controlled trial. Egypt Dent J. 2018;64:4057–4065. [Google Scholar]
  • 51.Eliezer M, Imber JC, Sculean A, Pandis N, Teich S. Hyaluronic acid as adjunctive to non-surgical and surgical periodontal therapy: A systematic review and meta-analysis. Clin Oral Invest. 2019;23:3423–3435. doi: 10.1007/s00784-019-03012-w. [DOI] [PubMed] [Google Scholar]
  • 52.Turgut Çankaya Z, Tamam E. An examination of the 2-year results obtained from hyaluronic acid filler injection for interdental papilla losses. Quintessence Int. 2020;51:274–284. doi: 10.3290/j.qi.a43938. [DOI] [PubMed] [Google Scholar]
  • 53.Aveic S, Craveiro RB, Wolf M, Fischer H. Current trends in in vitro modeling to mimic cellular crosstalk in periodontal tissue. Adv Healthc Mater. 2021;10(e2001269) doi: 10.1002/adhm.202001269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Vanden Bogaerde L. Treatment of infrabony periodontal defects with esterified hyaluronic acid: Clinical report of 19 consecutive lesions. Int J Periodontics Restorative Dent. 2009;29:315–323. [PubMed] [Google Scholar]
  • 55.Sukumar S, Ivo Dřízhal I. Hyaluronic acid and periodontitis. Acta Medica (Hradec Kralove) 2007;50:225–228. [PubMed] [Google Scholar]
  • 56.Rodríguez-Aranda M, Iborra-Badia I, Alpiste-Illueca F, Lopez-Roldan A. Hyaluronic acid for periodontal tissue regeneration in intrabony defects. A systematic review. Dentistry Review. 2022;2(100057) [Google Scholar]
  • 57.Nguyen TT, Ho HT, Huynh NC, Dien VHA, Vo TL. Hyaluronic acid 0.2% application enhanced periodontitis treatment in non-surgical phase. J Stoma. 2021;74:76–83. [Google Scholar]
  • 58.Rajan P, Baramappa R, Rao NM, Pavaluri AK, P I, Rahaman SM. Hyaluronic Acid as an adjunct to scaling and root planing in chronic periodontitis. A randomized clinical trial. J Clin Diagn Res. 2014;8:ZC11–ZC14. doi: 10.7860/JCDR/2014/8848.5237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Pilloni A, Schmidlin PR, Sahrmann P, Sculean A, Rojas MA. Effectiveness of adjunctive hyaluronic acid application in coronally advanced flap in Miller class I single gingival recession sites: A randomized controlled clinical trial. Clin Oral Investig. 2019;23:1133–1141. doi: 10.1007/s00784-018-2537-4. [DOI] [PubMed] [Google Scholar]
  • 60.Kumar R, Srinivas M, Pai J, Suragimath G, Prasad K, Polepalle T. Efficacy of hyaluronic acid (hyaluronan) in root coverage procedures as an adjunct to coronally advanced flap in Millers Class I recession: A clinical study. J Indian Soc Periodontol. 2014;18:746–750. doi: 10.4103/0972-124X.147411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Pitale U, Pal PC, Thakare G, Verma M, Dhakad S, Pandey R. Minimally invasive therapy for reconstruction of lost interdental papilla by using injectable hyaluronic acid filler. J Indian Soc Periodontol. 2021;25:22–28. doi: 10.4103/jisp.jisp_19_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Sadat Mansouri S, Ghasemi M, Salmani Z, Shams N. Clinical application of hyaluronic acid gel for reconstruction of interdental papilla at the esthetic zone. J Iran Dent Asso. 2013;25:208–213. [Google Scholar]
  • 63.Babgi W, Alhajaji M, Al-Mehmadi L, Elbaqli R, Khayat N, Aldahlawi S, Youssef AR. Effect of root conditioning agents hyaluronic acid, EDTA and chlorhexidine on the attachment of human gingival fibroblasts to healthy root surface. Saudi Dent J. 2021;33:342–347. doi: 10.1016/j.sdentj.2020.03.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Mamajiwala AS, Sethi KS, Raut CP, Karde PA, Mamajiwala BS. Clinical and radiographic evaluation of 0.8% hyaluronic acid as an adjunct to open flap debridement in the treatment of periodontal intrabony defects: Randomized controlled clinical trial. Clin Oral Investig. 2021;25:5257–5271. doi: 10.1007/s00784-021-03834-7. [DOI] [PubMed] [Google Scholar]
  • 65.Bhowmik E, Rao DPC. Clinicoradiographic evaluation of hyaluronan-nano hydroxyapatite composite graft in the management of periodontal infrabony defects. J Indian Soc Periodontol. 2021;25:220–227. doi: 10.4103/jisp.jisp_453_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Briguglio F, Briguglio E, Briguglio R, Cafiero C, Isola G. Treatment of infrabony periodontal defects using a resorbable biopolymer of hyaluronic acid: A randomized clinical trial. Quintessence Int. 2013;44:231–240. doi: 10.3290/j.qi.a29054. [DOI] [PubMed] [Google Scholar]
  • 67.Sehdev B, Bhongade ML, Ganji KK. Evaluation of effectiveness of hyaluronic acid in combination with bioresorbable membrane (poly lactic acid-poly glycolic acid) for the treatment of infrabony defects in humans: A clinical and radiographic study. J Indian Soc Periodontol. 2016;20:50–56. doi: 10.4103/0972-124X.170809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sánchez-Fernández E, Magán-Fernández A, O'Valle F, Bravo M, Mesa F. Hyaluronic acid reduces inflammation and crevicular fluid IL-1β concentrations in peri-implantitis: A randomized controlled clinical trial. J Periodontal Implant Sci. 2021;51:63–74. doi: 10.5051/jpis.1903660183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Dogan E, Dursun E, Tosun E, Bilgic E, Akman AC, Orhan K, Celik HH, Korkusuz P, Caglayan F. Evaluation of hyaluronic matrix efficacy in sinus augmentation: A randomized-controlled histomorphometric and micro-computed tomography analysis. Int J Oral Maxillofac Surg. 2017;46:931–937. doi: 10.1016/j.ijom.2017.03.003. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from Biomedical Reports are provided here courtesy of Spandidos Publications

RESOURCES